Anti-CD19 chimeric antigen receptor (CAR) T cell therapies can cause severe cytokine-release syndrome (CRS) and neurotoxicity, impeding their therapeutic application. Here we generated a new anti-CD19 CAR molecule (CD19-BBz(86)) derived from the CD19-BBz prototype bearing co-stimulatory 4-1...
2F) and CD107a expression on NK92 cells using flow cytometry (Fig. 2G, H). To assess whether CXCR2 over-expression could promote the migration of CAR-NK92 cells towards HCC cells, we conducted a transwell assay (Fig. 2I), in which control medium or culture supernatant of Huh-7 or ...
4 Treatment of B-cell malignancies with anti-CD19 CAR T cells results in durable remission in a significant number of patients. This treatment is associated with B-cell aplasia because of endogenous CD19 expression on B cells. Additionally, treatment with anti-CD19 CAR T-cell therapy can ...
CAR T cells CLL chronic lymphocytic leukemia CD19 GMP clinical cell production Introduction Chronic lymphocytic leukemia (CLL) is one of the most common hematological malignancies with an estimated incidence of 18,740 in the United States for 2023.1 CLL is a clonal proliferation of CD19+CD5+ B...
Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy. Nat. Med. 28, 713–723 (2022). Article CAS PubMed PubMed Central Google Scholar Lobionda, S., Sittipo, P., Kwon, H. Y. & Lee, Y. K. The role of gut microbiota in intestinal inflammation ...
Anti-mouse CD19 CAR T cells containing CD28 and CD3ζ13(Extended Data Fig. 1a) were generated; CAR expression correlated strongly with epidermal growth factor receptor (EGFR) reporter expression, allowing the use of EGFR for tracking CAR+ cells (Extended Data Fig. 1b). CAR T cells were ...
Chimeric antigen receptor (CAR) T cell therapy, especially anti-CD19 CAR T cell therapy, has shown remarkable anticancer activity in patients with relapsed/refractory acute lymphoblastic leukemia, demonstrating an inspiring complete remission rate. However, with extension of the follow-up period, the ...
Magnetic bead immunodepletion (Dynal) removed CD19+, CD4+, and CD14+ cells to obtain CD8+ ve T-cell populations. Quantitative RT-PCR on normal and neoplastic human cells RNA was isolated from viably frozen specimens or cell lines growing in logarithmic phase using RNAqueous-4 PCR kits (Ambion...
Base editing of PIK3CD and PIK3R1 variants in T cells with an engineered T cell receptor specific to a melanoma epitope or in different generations of CD19 chimeric antigen receptor (CAR) T cells demonstrates that discovered GOF variants, but not LOF or silent mutation controls, enhanced ...
A. et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat. Med. 24, 563 (2018). CAS PubMed PubMed Central Google Scholar He, S. et al. Ezh2 phosphorylation state determines its capacity to maintain CD8+...